Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute

Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute


The damages award is far less than the $2 billion Merck had demanded. On Tuesday, the same jury in San Jose, California, upheld the validity of the patents, which lie at the heart of the dispute over Gilead's blockbuster drugs Sovaldi and Harvoni.



from Biotech News